1. Home
  2. BBWI vs CRNX Comparison

BBWI vs CRNX Comparison

Compare BBWI & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bath & Body Works Inc.

BBWI

Bath & Body Works Inc.

HOLD

Current Price

$20.04

Market Cap

4.0B

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$83.68

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBWI
CRNX
Founded
1963
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
3.9B
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
BBWI
CRNX
Price
$20.04
$83.68
Analyst Decision
Hold
Strong Buy
Analyst Count
15
8
Target Price
$24.88
$76.75
AVG Volume (30 Days)
4.9M
7.0M
Earning Date
05-28-2026
05-07-2026
Dividend Yield
4.36%
N/A
EPS Growth
N/A
N/A
EPS
0.90
N/A
Revenue
$7,291,000,000.00
$1,039,000.00
Revenue This Year
N/A
$720.10
Revenue Next Year
$2.19
$184.67
P/E Ratio
$22.07
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.28
$25.83
52 Week High
$32.32
$84.00

Technical Indicators

Market Signals
Indicator
BBWI
CRNX
Relative Strength Index (RSI) 49.02 91.05
Support Level $18.81 $43.40
Resistance Level $21.46 N/A
Average True Range (ATR) 0.80 0.19
MACD -0.09 -1.44
Stochastic Oscillator 39.51 40.51

Price Performance

Historical Comparison
BBWI
CRNX

About BBWI Bath & Body Works Inc.

Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with just 4% of sales from international markets in fiscal 2025. For fiscal 2025, 77% of sales stemmed from the brick-and-mortar network of more than 1,900 retail stores, similar to 2024 levels, as consumer shopping patterns remained normal. Future growth is expected from store upgrades, digital and international channels, as well as adjacent category expansions like men's and lip.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: